Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 12/20 | 0.56 |
| ▸ | CACNA1I | Q9P0X4 | 11/20 | 0.56 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4269612 | 0.93 | KCNH2 (0.65) | KCNH2CACNA1ICACNA1HCYP2D6CCR2 | |
| SCHEMBL8373973 | 0.92 | CACNA1I (0.60) | KCNH2CACNA1ICACNA1HCYP2D6CCR2 | |
| SCHEMBL4273171 | 0.89 | KCNH2 (0.58) | KCNH2CACNA1ICACNA1HCYP2D6CCR2 | |
| SCHEMBL8372955 | 0.89 | KCNH2 (0.58) | KCNH2CACNA1ICACNA1HCYP2D6CCR2 | |
| SCHEMBL8370965 | 0.87 | KCNH2 (0.58) | KCNH2CACNA1ICACNA1HCYP2D6CCR2 | |
| SCHEMBL17860746 | 0.84 | CACNA1I (0.64) | KCNH2CACNA1ICACNA1HCYP2D6CCR2 | |
| SCHEMBL4270899 | 0.84 | CACNA1I (0.69) | KCNH2CACNA1ICACNA1HCYP2D6MCHR1 | |
| SCHEMBL17860747 | 0.83 | CACNA1I (0.66) | KCNH2CACNA1ICACNA1HCYP2D6CCR2 | |
| SCHEMBL4274640 | 0.83 | KCNH2 (0.65) | KCNH2CACNA1ICACNA1HCYP2D6CCR2 | |
| SCHEMBL8372942 | 0.83 | KCNH2 (0.64) | KCNH2CACNA1ICACNA1HCYP2D6CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160175315-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS, LTD. (CA) | 2016-06-23 | — | — | US | disclosed |
| US-20090298883-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MARK G. DEGIACOMO, CHAPTER 7 TRUSTEE OF EPIRUS BIOPHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298883-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1H, CACNA1B | KCNH2 60/4885CACNA1I 4/4885CACNA1H 2/4885 |
| US-20160175315-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1H, CACNA1B | KCNH2 60/4885CACNA1I 4/4885CACNA1H 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.